Press Releases
- Dec 11, 2017Teva also agrees to withdraw Irish equivalent to U.S. patents from litigation in Ireland
- Dec 1, 2017Mylan anticipates potentially being the first company to provide patient access to a biosimilar to Herceptin®, representing a significant milestone for Mylan, Biocon and the overall healthcare system
- Nov 13, 2017Filing Supported by Positive Results from Two Pivotal Phase 3 Efficacy Studies and One 12-Month Phase 3 Safety Study
- Nov 9, 2017
- Nov 1, 2017Presentations Highlight 24-Hour Serial Spirometry Subgroup Findings from Two Replicate Pivotal Phase 3 Studies; Improvements Observed in St. George's Respiratory Questionnaire and COPD Assessment Test Results
- Oct 27, 2017- 2017 marks the five-year anniversary of Mylan's EpiPen4Schools® program.
- Oct 16, 2017
- Oct 5, 2017Mylan Has Exclusive Rights for Glatiramer Acetate in Several Key European Markets
- Oct 4, 2017More than 6 Million Doses of Medicine Plus Financial and Other Assistance Provided to Affected Areas
- Oct 3, 2017Mylan Also Receives U.S. FDA Approval of Generic for Copaxone® 20 mg/mL Once-Daily
- Oct 2, 2017
- Sep 29, 2017
